¹Ì±¹¿¡¼ 36 ¿Ü·¡ º´µ¿¿¡¼ Ä¡·á ¹Þ´Â 2 Çü ´ç´¢ ȯÀÚÀÇ Ç÷´çÀº rosiglitazone°ú metformin º´¿ë Åõ¿©·Î À¯ÀǼº ÀÖ°Ô °³¼±µÇ¾ú´Ù.
º´¿ë ¿ä¹ýÀº Àν´¸° ÀúÇ×¼ºÀÇ Á¶ÀýÀ» °³¼±½ÃÅ°°í ÃéÀå¿¡ ÀÇÇÑ Àν´¸° »ý»êÀ» Áõ°¡½ÃÄ×´Ù – ÀÌµé µÎ °¡Áö ¾à¹°ÀÇ º´¿ë Åõ¿©°¡ ÀÌ º´ÀÇ ¾Çȸ¦ Áö¿¬ ½ÃÅ°°Å³ª ¿¹¹æÇÑ´Ù°í º¸°íµÇ¾ú´Ù
ÀÌµé µÎ °¡Áö ¾à¹°ÀÌ ¼·Î ´Ù¸¥ ±âÀüÀ¸·Î ÀÛ¿ëÇÑ´Ù´Â °ÍÀ» ¾Ë¾Æ Â÷¸° ¿¬±¸ÀÚµéÀºmetformin À¯Áö·®À¸·Î Á¶ÀýÀÌ Àß ¾È µÇ´Â ȯÀÚ¿¡°Ô rosiglitazoneÀÌ µµ¿òÀ» ÁÙ ¼öµµ ÀÖ´Ù°í ¸»Çß´Ù
( Âü°í ¹®Çå :¹Ì±¹ ÀÇÇÐ ÀâÁö 283:13:
1695-1702)
Blood sugar levels in type 2 diabetes patients treated in 36 outpatient centers in the U.S. were significantly improved by the addition of rosiglitazone(Avandia) to metformin (Glucophage)therapy.
The combined therapy improved the control of insulin resistance and increased insulin production by the pancreas, suggesting that the combined drug therapy may delay or prevent disease progression. Researchers, noting the two drugs act via different mechanisms, said patients whose disease is poorly controlled with a maintenance dose of metformin may find rosiglitazone helpful.
(source : JAMA, 283:13:1695-1702)
< ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |
|
|
|
|
ÀÌ ±â»ç¿¡ ´ëÇÑ ´ñ±Û À̾߱â (0) |
|
|
|